Cutaneous B cell pseudolymphoma treated with rituximab and methotrexate
Cutaneous B cell pseudolymphoma (CBPL), or cutaneous lymphoid hyperplasia, is the most common pseudolymphoma. It typically responds well to local treatment and follows a benign course. Herein, we describe the unique case of a patient with CBPL that was refractory to a variety of treatments, with sub...
Gespeichert in:
| Veröffentlicht in: | Dermatology online journal 2021-09, Vol.27 (9) |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 9 |
| container_start_page | |
| container_title | Dermatology online journal |
| container_volume | 27 |
| creator | Besch-Stokes, Jake G Patel, Meera H Brumfiel, Caitlin M Costello, Collin M Rule, William Rosenthal, Allison Pittelkow, Mark R DiCaudo, David J Mangold, Aaron R |
| description | Cutaneous B cell pseudolymphoma (CBPL), or cutaneous lymphoid hyperplasia, is the most common pseudolymphoma. It typically responds well to local treatment and follows a benign course. Herein, we describe the unique case of a patient with CBPL that was refractory to a variety of treatments, with subsequent response to rituximab followed by methotrexate. This case explores the complex interplay of T and B lymphocytes, and the potential role of perifollicular T cells in treatment resistant CBPL. Further, it describes the additive therapeutic effect of rituximab and methotrexate to target both B cell and T cell populations in CBPL, a strategy already employed in a number of other conditions. |
| doi_str_mv | 10.5070/D327955138 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2596020061</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2595999334</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2668-e4b97bfdea9ef158a94b4cbf97162b946d830606e26b0355b579f62027378ec53</originalsourceid><addsrcrecordid>eNpdkN1LwzAUxYMobk5f_AMk4IsI1TRpvh516hQGvuhzSdpb1tGuNWlw--_N2PzAl3sv3B-Hcw5C5ym54USS2wdGpeY8ZeoAjVOiZELjPPxzj9CJ90tCKMk4O0YjlknOtSJjNJuGwaygCx7f4wKaBvceQtk1m7ZfdK3BgwMzQIk_62GBXT2Edd0ai82qxC0Miy7-1xE4RUeVaTyc7fcEvT89vk2fk_nr7GV6N08KKoRKILNa2qoEo6FKuTI6s1lhKy1TQa3ORKkYEUQAFZYwzi2XuhKUUMmkgoKzCbra6fau-wjgh7yt_db3LkROuRYxJhFpRC__ocsuuFV0t6W41pqxLFLXO6pwnfcOqrx3MaHb5CnJt_Xmv_VG-GIvGWwL5Q_63Sf7Am-eczM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2595999334</pqid></control><display><type>article</type><title>Cutaneous B cell pseudolymphoma treated with rituximab and methotrexate</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Besch-Stokes, Jake G ; Patel, Meera H ; Brumfiel, Caitlin M ; Costello, Collin M ; Rule, William ; Rosenthal, Allison ; Pittelkow, Mark R ; DiCaudo, David J ; Mangold, Aaron R</creator><creatorcontrib>Besch-Stokes, Jake G ; Patel, Meera H ; Brumfiel, Caitlin M ; Costello, Collin M ; Rule, William ; Rosenthal, Allison ; Pittelkow, Mark R ; DiCaudo, David J ; Mangold, Aaron R</creatorcontrib><description>Cutaneous B cell pseudolymphoma (CBPL), or cutaneous lymphoid hyperplasia, is the most common pseudolymphoma. It typically responds well to local treatment and follows a benign course. Herein, we describe the unique case of a patient with CBPL that was refractory to a variety of treatments, with subsequent response to rituximab followed by methotrexate. This case explores the complex interplay of T and B lymphocytes, and the potential role of perifollicular T cells in treatment resistant CBPL. Further, it describes the additive therapeutic effect of rituximab and methotrexate to target both B cell and T cell populations in CBPL, a strategy already employed in a number of other conditions.</description><identifier>ISSN: 1087-2108</identifier><identifier>EISSN: 1087-2108</identifier><identifier>DOI: 10.5070/D327955138</identifier><identifier>PMID: 34755980</identifier><language>eng</language><publisher>United States: University of California Digital Library - eScholarship</publisher><subject>Aged ; Antineoplastic Agents, Immunological - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; B-Lymphocytes - drug effects ; Drug Resistance ; Drug therapy ; Humans ; Immunotherapy ; Lymphocytes ; Lymphoma ; Male ; Methotrexate - administration & dosage ; Monoclonal antibodies ; Pseudolymphoma - drug therapy ; Pseudolymphoma - immunology ; Rituximab - administration & dosage ; Skin - immunology ; Skin - pathology ; Skin Neoplasms - drug therapy ; T-Lymphocytes - drug effects</subject><ispartof>Dermatology online journal, 2021-09, Vol.27 (9)</ispartof><rights>2021. Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the associated terms available at https://creativecommons.org/licenses/by-nc-nd/4.0</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2668-e4b97bfdea9ef158a94b4cbf97162b946d830606e26b0355b579f62027378ec53</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34755980$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Besch-Stokes, Jake G</creatorcontrib><creatorcontrib>Patel, Meera H</creatorcontrib><creatorcontrib>Brumfiel, Caitlin M</creatorcontrib><creatorcontrib>Costello, Collin M</creatorcontrib><creatorcontrib>Rule, William</creatorcontrib><creatorcontrib>Rosenthal, Allison</creatorcontrib><creatorcontrib>Pittelkow, Mark R</creatorcontrib><creatorcontrib>DiCaudo, David J</creatorcontrib><creatorcontrib>Mangold, Aaron R</creatorcontrib><title>Cutaneous B cell pseudolymphoma treated with rituximab and methotrexate</title><title>Dermatology online journal</title><addtitle>Dermatol Online J</addtitle><description>Cutaneous B cell pseudolymphoma (CBPL), or cutaneous lymphoid hyperplasia, is the most common pseudolymphoma. It typically responds well to local treatment and follows a benign course. Herein, we describe the unique case of a patient with CBPL that was refractory to a variety of treatments, with subsequent response to rituximab followed by methotrexate. This case explores the complex interplay of T and B lymphocytes, and the potential role of perifollicular T cells in treatment resistant CBPL. Further, it describes the additive therapeutic effect of rituximab and methotrexate to target both B cell and T cell populations in CBPL, a strategy already employed in a number of other conditions.</description><subject>Aged</subject><subject>Antineoplastic Agents, Immunological - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>B-Lymphocytes - drug effects</subject><subject>Drug Resistance</subject><subject>Drug therapy</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Lymphocytes</subject><subject>Lymphoma</subject><subject>Male</subject><subject>Methotrexate - administration & dosage</subject><subject>Monoclonal antibodies</subject><subject>Pseudolymphoma - drug therapy</subject><subject>Pseudolymphoma - immunology</subject><subject>Rituximab - administration & dosage</subject><subject>Skin - immunology</subject><subject>Skin - pathology</subject><subject>Skin Neoplasms - drug therapy</subject><subject>T-Lymphocytes - drug effects</subject><issn>1087-2108</issn><issn>1087-2108</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkN1LwzAUxYMobk5f_AMk4IsI1TRpvh516hQGvuhzSdpb1tGuNWlw--_N2PzAl3sv3B-Hcw5C5ym54USS2wdGpeY8ZeoAjVOiZELjPPxzj9CJ90tCKMk4O0YjlknOtSJjNJuGwaygCx7f4wKaBvceQtk1m7ZfdK3BgwMzQIk_62GBXT2Edd0ai82qxC0Miy7-1xE4RUeVaTyc7fcEvT89vk2fk_nr7GV6N08KKoRKILNa2qoEo6FKuTI6s1lhKy1TQa3ORKkYEUQAFZYwzi2XuhKUUMmkgoKzCbra6fau-wjgh7yt_db3LkROuRYxJhFpRC__ocsuuFV0t6W41pqxLFLXO6pwnfcOqrx3MaHb5CnJt_Xmv_VG-GIvGWwL5Q_63Sf7Am-eczM</recordid><startdate>20210915</startdate><enddate>20210915</enddate><creator>Besch-Stokes, Jake G</creator><creator>Patel, Meera H</creator><creator>Brumfiel, Caitlin M</creator><creator>Costello, Collin M</creator><creator>Rule, William</creator><creator>Rosenthal, Allison</creator><creator>Pittelkow, Mark R</creator><creator>DiCaudo, David J</creator><creator>Mangold, Aaron R</creator><general>University of California Digital Library - eScholarship</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20210915</creationdate><title>Cutaneous B cell pseudolymphoma treated with rituximab and methotrexate</title><author>Besch-Stokes, Jake G ; Patel, Meera H ; Brumfiel, Caitlin M ; Costello, Collin M ; Rule, William ; Rosenthal, Allison ; Pittelkow, Mark R ; DiCaudo, David J ; Mangold, Aaron R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2668-e4b97bfdea9ef158a94b4cbf97162b946d830606e26b0355b579f62027378ec53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Antineoplastic Agents, Immunological - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>B-Lymphocytes - drug effects</topic><topic>Drug Resistance</topic><topic>Drug therapy</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Lymphocytes</topic><topic>Lymphoma</topic><topic>Male</topic><topic>Methotrexate - administration & dosage</topic><topic>Monoclonal antibodies</topic><topic>Pseudolymphoma - drug therapy</topic><topic>Pseudolymphoma - immunology</topic><topic>Rituximab - administration & dosage</topic><topic>Skin - immunology</topic><topic>Skin - pathology</topic><topic>Skin Neoplasms - drug therapy</topic><topic>T-Lymphocytes - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Besch-Stokes, Jake G</creatorcontrib><creatorcontrib>Patel, Meera H</creatorcontrib><creatorcontrib>Brumfiel, Caitlin M</creatorcontrib><creatorcontrib>Costello, Collin M</creatorcontrib><creatorcontrib>Rule, William</creatorcontrib><creatorcontrib>Rosenthal, Allison</creatorcontrib><creatorcontrib>Pittelkow, Mark R</creatorcontrib><creatorcontrib>DiCaudo, David J</creatorcontrib><creatorcontrib>Mangold, Aaron R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Dermatology online journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Besch-Stokes, Jake G</au><au>Patel, Meera H</au><au>Brumfiel, Caitlin M</au><au>Costello, Collin M</au><au>Rule, William</au><au>Rosenthal, Allison</au><au>Pittelkow, Mark R</au><au>DiCaudo, David J</au><au>Mangold, Aaron R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cutaneous B cell pseudolymphoma treated with rituximab and methotrexate</atitle><jtitle>Dermatology online journal</jtitle><addtitle>Dermatol Online J</addtitle><date>2021-09-15</date><risdate>2021</risdate><volume>27</volume><issue>9</issue><issn>1087-2108</issn><eissn>1087-2108</eissn><abstract>Cutaneous B cell pseudolymphoma (CBPL), or cutaneous lymphoid hyperplasia, is the most common pseudolymphoma. It typically responds well to local treatment and follows a benign course. Herein, we describe the unique case of a patient with CBPL that was refractory to a variety of treatments, with subsequent response to rituximab followed by methotrexate. This case explores the complex interplay of T and B lymphocytes, and the potential role of perifollicular T cells in treatment resistant CBPL. Further, it describes the additive therapeutic effect of rituximab and methotrexate to target both B cell and T cell populations in CBPL, a strategy already employed in a number of other conditions.</abstract><cop>United States</cop><pub>University of California Digital Library - eScholarship</pub><pmid>34755980</pmid><doi>10.5070/D327955138</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1087-2108 |
| ispartof | Dermatology online journal, 2021-09, Vol.27 (9) |
| issn | 1087-2108 1087-2108 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2596020061 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use B-Lymphocytes - drug effects Drug Resistance Drug therapy Humans Immunotherapy Lymphocytes Lymphoma Male Methotrexate - administration & dosage Monoclonal antibodies Pseudolymphoma - drug therapy Pseudolymphoma - immunology Rituximab - administration & dosage Skin - immunology Skin - pathology Skin Neoplasms - drug therapy T-Lymphocytes - drug effects |
| title | Cutaneous B cell pseudolymphoma treated with rituximab and methotrexate |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A02%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cutaneous%20B%20cell%20pseudolymphoma%20treated%20with%20rituximab%20and%20methotrexate&rft.jtitle=Dermatology%20online%20journal&rft.au=Besch-Stokes,%20Jake%20G&rft.date=2021-09-15&rft.volume=27&rft.issue=9&rft.issn=1087-2108&rft.eissn=1087-2108&rft_id=info:doi/10.5070/D327955138&rft_dat=%3Cproquest_cross%3E2595999334%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2595999334&rft_id=info:pmid/34755980&rfr_iscdi=true |